Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aquinox Pharmaceuticals Inc    AQXP

AQUINOX PHARMACEUTICALS INC (AQXP)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/10/2018 10/11/2018 10/12/2018 10/15/2018 10/16/2018 Date
2.62(c) 2.67(c) 2.61(c) 2.6(c) 2.63(c) Last
206 270 90 870 72 661 433 947 259 795 Volume
-2.24% +1.91% -2.25% -0.38% +1.15% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -
Net income 2018 -36,9 M
Debt 2018 -
Yield 2018 -
Sales 2019 -
EBIT 2019 -
Net income 2019 -60,3 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 0
Capitalization 61,4 M
More Financials
Company
Aquinox Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company.It discovers and develops targeted therapeutics for inflammation and immuno-oncology.It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling... 
Sector
Pharmaceuticals
Calendar
11/07Earnings Release
More about the company
Latest news on AQUINOX PHARMACEUTICALS IN
09/07AQUINOX PHARMACEUTICALS, INC : Termination of a Material Definitive Agreement (f..
AQ
08/14AQUINOX PHARMACEUTICALS : Announces Second Quarter 2018 Financial Results
AQ
08/08AQUINOX PHARMACEUTICALS, INC : Results of Operations and Financial Condition, Fi..
AQ
08/08AQUINOX PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
AQ
08/08AQUINOX : 2Q Earnings Snapshot
AQ
08/08Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results
GL
07/11AQUINOX PHARMACEUTICALS : After rosiptor`s phase 3 rout, Aquinox to cut staff by..
AQ
07/09AQUINOX PHARMACEUTICALS, INC : Costs Associated with Exit or Disposal Activities..
AQ
07/02AQUINOX PHARMACEUTICALS : Announces Topline Results of Phase 3 LEADERSHIP 301 Cl..
AQ
06/28AQUINOX PHARMACEUTICALS : Pharma (AQXP) Phase 3 LEADERSHIP 301 Clinical Trial in..
AQ
More news
Sector news : Pharmaceuticals - NEC
09:02aRoche Sales Grow, Buoyed by New Drugs -- Update
DJ
08:48aJOHNSON & JOHNSON : J&J Raises Forecast as Sales Rise
DJ
08:10aRoche posts modest third-quarter sales beat as new drugs offset hit from copi..
RE
07:32aRoche Sales Grow, Buoyed by New Drugs
DJ
10/16Stocks rebound with earnings in focus; oil up on supply concern
RE
More sector news : Pharmaceuticals - NEC
Latest Tweets
10/02Aquinox Pharmaceuticals Inc $AQXP Given Average Recommendation of “Hold” by A.. 
09/27$AQXP thin name trading under cash levels (nearly $4.34 per share in cash) wi.. 
09/24$AQXP back over $3 (showing some strength this morning) 
09/24Want the latest analyst ratings on $DNLI $CURO $AQXP $AVNU $TMK? Get Them Del.. 
09/10Aquinox Pharmaceuticals Inc $AQXP Given Consensus Recommendation of “Hold” by.. 
More tweets
Qtime:23
News from SeekingAlpha
08/15After Hours Gainers / Losers (08/15/2018) 
08/08PREMARKET GAINERS AS OF 9 : 05 am (08/08/2018) 
08/08Aquinox Pharma beats by $0.24, beats on revenue 
07/22Recognize These Week 29 Winners? Top 10 Stocks Across Multiple Financial Algo.. 
07/17Midday Gainers / Losers (07/17/2018) 
Chart AQUINOX PHARMACEUTICALS INC
Duration : Period :
Aquinox Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AQUINOX PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 14,5 $
Spread / Average Target 451%
EPS Revisions
Managers
NameTitle
David J. Main Chairman, President & Chief Executive Officer
Lloyd Mackenzie Chief Operating Officer
Kamran Alam Chief Financial Officer, Secretary & VP
Daniel J. Levitt Independent Director
Robert E. Pelzer Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AQUINOX PHARMACEUTICALS INC-77.89%61
JOHNSON & JOHNSON-4.19%359 141
PFIZER20.87%256 643
NOVARTIS0.07%212 170
ROCHE HOLDING LTD.-4.56%204 254
MERCK AND COMPANY23.44%185 661